揭示非小细胞肺癌中的免疫肿瘤微环境，以了解对检查点阻断和放疗的反应率。
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.
作者信息
Schoenhals Jonathan E, Seyedin Steven N, Anderson Clark, Brooks Eric D, Li Yun R, Younes Ahmed I, Niknam Sharareh, Li Ailin, Barsoumian Hampartsoum B, Cortez Maria Angelica, Welsh James W
机构信息
Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
出版信息
Transl Lung Cancer Res. 2017 Apr;6(2):148-158. doi: 10.21037/tlcr.2017.03.06.
Abstract
The study of immunology has led to breakthroughs in treating non-small cell lung cancer (NSCLC). The recent approval of an anti-PD1 checkpoint drug for NSCLC has generated much interest in novel combination therapies that might provide further benefit for patients. However, a better understanding of which combinations may (or may not) work in NSCLC requires understanding the lung immune microenvironment under homeostatic conditions and the changes in that microenvironment in the setting of cancer progression and with radiotherapy. This review provides background information on immune cells found in the lung and the prognostic significance of these cell types in lung cancer. It also addresses current clinical directions for the combination of checkpoint inhibitors with radiation for NSCLC.
摘要
免疫学研究已在非小细胞肺癌（NSCLC）治疗方面取得突破。一种抗PD1检查点药物近期获批用于NSCLC治疗，这引发了人们对可能为患者带来更多益处的新型联合疗法的浓厚兴趣。然而，要更好地理解哪些联合疗法可能（或不可能）对NSCLC有效，需要了解稳态条件下的肺部免疫微环境以及癌症进展和放疗情况下该微环境的变化。本综述提供了有关肺部发现的免疫细胞的背景信息以及这些细胞类型在肺癌中的预后意义。它还探讨了目前将检查点抑制剂与放疗联合用于NSCLC治疗的临床方向。
相似文献
1
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.揭示非小细胞肺癌中的免疫肿瘤微环境，以了解对检查点阻断和放疗的反应率。
Transl Lung Cancer Res. 2017 Apr;6(2):148-158. doi: 10.21037/tlcr.2017.03.06.
2
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).术前 PD1 检查点阻断和核因子κB 受体激活剂配体（RANKL）抑制在非小细胞肺癌（NSCLC）中的药效学：一项多中心、开放标签、1B/2 期、转化试验（POPCORN）的研究方案。
Trials. 2019 Dec 19;20(1):753. doi: 10.1186/s13063-019-3951-x.
3
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.非小细胞肺癌脑转移患者的免疫治疗。了解脑肿瘤微环境并剖析临床免疫检查点阻断治疗的结果。
Cancer Treat Rev. 2020 Sep;89:102067. doi: 10.1016/j.ctrv.2020.102067. Epub 2020 Jul 7.
4
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.免疫检查点抑制剂联合化疗治疗非小细胞肺癌的分子基础和原理。
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
5
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
6
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.基质 PD-L1 阳性调节性 T 细胞和 PD-1 阳性 CD8 阳性 T 细胞定义了不同亚组非小细胞肺癌对 PD-1/PD-L1 阻断免疫治疗的反应。
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
7
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.表达检查点抑制剂的溶瘤新城疫病毒作为一种放射性增强剂用于治疗鼠黑色素瘤。
EBioMedicine. 2019 Nov;49:96-105. doi: 10.1016/j.ebiom.2019.10.032. Epub 2019 Oct 29.
8
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.非小细胞肺癌中的免疫治疗联合策略（非化疗）
J Thorac Dis. 2018 Feb;10(Suppl 3):S433-S450. doi: 10.21037/jtd.2017.12.120.
9
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.外周血 PD1 阳性 CD4 T 淋巴细胞计数可预测接受免疫检查点抑制剂治疗的非小细胞肺癌患者的无进展生存期。
Anticancer Res. 2019 Dec;39(12):6887-6893. doi: 10.21873/anticanres.13908.
10
Recent Advances in Immunotherapy in Metastatic NSCLC.转移性非小细胞肺癌免疫治疗的最新进展
Front Oncol. 2016 Nov 14;6:239. doi: 10.3389/fonc.2016.00239. eCollection 2016.
引用本文的文献
1
Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure.应对肺癌治疗中耐药性的复杂性：机制、类器官模型及克服治疗失败的策略
Cancers (Basel). 2024 Nov 28;16(23):3996. doi: 10.3390/cancers16233996.
2
Immune killer cells treatment for previously treated stage IV NSCLC patients.免疫杀伤细胞治疗先前治疗过的 IV 期 NSCLC 患者。
Sci Rep. 2024 Aug 21;14(1):19374. doi: 10.1038/s41598-024-69587-x.
3
Implications of ZNF334 gene in lymph node metastasis of lung SCC: potential bypassing of cellular senescence.ZNF334 基因对肺鳞癌淋巴结转移的影响：潜在的绕过细胞衰老。
J Transl Med. 2024 Apr 18;22(1):372. doi: 10.1186/s12967-024-05115-9.
4
A Novel Gene Signature based on Immune Cell Infiltration Landscape Predicts Prognosis in Lung Adenocarcinoma Patients.基于免疫细胞浸润景观的新型基因特征可预测肺腺癌患者的预后。
Curr Med Chem. 2024;31(38):6319-6335. doi: 10.2174/0109298673293174240320053546.
5
Potential association of HSPD1 with dysregulations in ribosome biogenesis and immune cell infiltration in lung adenocarcinoma: An integrated bioinformatic approach.HSPD1 与肺腺癌核糖体生物发生失调和免疫细胞浸润的潜在关联：一种综合的生物信息学方法。
Cancer Biomark. 2024;39(3):155-170. doi: 10.3233/CBM-220442.
6
The Voltage-Gated Hv1 H Channel Is Expressed in Tumor-Infiltrating Myeloid-Derived Suppressor Cells.电压门控 Hv1 H 通道在肿瘤浸润髓源性抑制细胞中表达。
Int J Mol Sci. 2023 Mar 25;24(7):6216. doi: 10.3390/ijms24076216.
7
APC mutation correlated with poor response of immunotherapy in colon cancer.APC 突变与结肠癌免疫治疗反应不良相关。
BMC Gastroenterol. 2023 Mar 28;23(1):95. doi: 10.1186/s12876-023-02725-3.
8
Preliminary Study on Natural Killer Cell Activity for Interferon-Gamma Production after Gamma Knife Radiosurgery for Brain Tumors.脑肿瘤伽玛刀放射治疗后自然杀伤细胞活性对γ干扰素产生的初步研究
J Korean Neurosurg Soc. 2022 Nov;65(6):861-867. doi: 10.3340/jkns.2020.0339. Epub 2022 Nov 1.
9
Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review.长链非编码RNA、免疫疗法及DNA甲基化在肺鳞状细胞癌中的临床病理意义：一项叙述性综述
Transl Cancer Res. 2021 Dec;10(12):5406-5429. doi: 10.21037/tcr-21-1607.
10
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.寡转移和寡进展性非小细胞肺癌肿瘤微环境的叙述性综述：仍有许多工作要做。
Transl Lung Cancer Res. 2021 Jul;10(7):3369-3384. doi: 10.21037/tlcr-20-1134.
本文引用的文献
1
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.肿瘤中I型干扰素信号通路的抑制介导了对抗PD-1治疗的耐药性，而放疗可克服这种耐药性。
Cancer Res. 2017 Feb 15;77(4):839-850. doi: 10.1158/0008-5472.CAN-15-3142. Epub 2016 Nov 7.
2
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.一线全身治疗后无进展的寡转移性非小细胞肺癌患者的局部巩固治疗与维持治疗或观察比较：一项多中心、随机、对照、2期研究
Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.
3
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.放疗与 PD-1 阻断联合治疗 Kras 突变型肺癌。
JCI Insight. 2016 Jun 16;1(9):e87415. doi: 10.1172/jci.insight.87415.
4
Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells.共济失调毛细血管扩张症突变激活介导肿瘤坏死因子-α诱导肺癌细胞中基质金属蛋白酶-13的上调和转移。
Oncotarget. 2016 Sep 20;7(38):62070-62083. doi: 10.18632/oncotarget.11386.
5
A High-Dimensional Atlas of Human T Cell Diversity Reveals Tissue-Specific Trafficking and Cytokine Signatures.人类 T 细胞多样性的高维图谱揭示了组织特异性迁移和细胞因子特征。
Immunity. 2016 Aug 16;45(2):442-56. doi: 10.1016/j.immuni.2016.07.007. Epub 2016 Aug 9.
6
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.立体定向消融放疗联合免疫疗法治疗实体瘤
Cancer J. 2016 Jul-Aug;22(4):257-66. doi: 10.1097/PPO.0000000000000210.
7
Interleukins 1 and 6 as Main Mediators of Inflammation and Cancer.白细胞介素1和6作为炎症和癌症的主要介质。
Biochemistry (Mosc). 2016 Feb;81(2):80-90. doi: 10.1134/S0006297916020024.
8
Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.放射治疗联合免疫治疗的临床前理论依据与临床考量：超越局部控制
Cancer J. 2016 Mar-Apr;22(2):130-7. doi: 10.1097/PPO.0000000000000181.
9
Single-cell Transcriptome Study as Big Data.作为大数据的单细胞转录组研究
Genomics Proteomics Bioinformatics. 2016 Feb;14(1):21-30. doi: 10.1016/j.gpb.2016.01.005. Epub 2016 Feb 11.
10
Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions.肿瘤浸润淋巴细胞疗法：解决常见问题
Cancer J. 2015 Nov-Dec;21(6):450-64. doi: 10.1097/PPO.0000000000000162.
Zotero 插件